Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib PK in Renal Impairment
NCT04037865Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ritlecitinib tosilate in alopecia areata (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at Day 11 and Area Under the Concentration-Time Curve From Time 0 to 24 Hours. Started Aug 2019; status: terminated.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT04037865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037865.